Stock comparison
Bio-Rad Laboratories
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BIO
Bio-Rad Laboratories
Market cap
$7.78B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BIO | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 79B | HALO |
| Benjamin Graham | 48D | 83A | HALO |
| Philip Fisher | 30F | 65B | HALO |
| Peter Lynch | 10F | 53D | HALO |
| Joel Greenblatt | 42D | 40D | BIO |
| Charlie Munger | 34F | 80C | HALO |
| Terry Smith | 26F | 84A | HALO |
Side-by-side metrics
| Metric | BIO | HALO |
|---|---|---|
| Market cap | $7.78B | $8.1B |
| P/E (TTM) | 39.5x | 24.0x |
| EV/EBIT | 28.0x | 10.2x |
| ROIC (TTM) | 1.95% | 23.65% |
| Gross margin | 51.87% | 81.24% |
| Net margin | 6.52% | 23.13% |
| Revenue CAGR 5y | -3.04% | 33.23% |
| EPS CAGR 5y | -33.51% | -1.98% |
| Debt / Equity | 0.2x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BIO leads on
- Debt / Equity0.2xvs 1.0x+79%
HALO leads on
- Revenue CAGR 5y33.23%vs -3.04%+109%
- EPS CAGR 5y-1.98%vs -33.51%+94%
- ROIC (TTM)23.65%vs 1.95%+92%
- Net margin23.13%vs 6.52%+72%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.